日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

一项针对晚期实体瘤患者的SHP2抑制剂BBP-398的首次人体I期研究

Falchook, Gerald; Braganca Xavier, Camila; Van Veenhuyzen, David; Malhotra, Jyoti; Sadeghi, Saeed; Kalebasty, Arash Rezazadeh; Wood, Lauren; Rahman, Faisal; Li, Elizabeth; Pak, Yvonne; Khalil, Maya; Spira, Alexander I; Sommerhalder, David; Garrido-Laguna, Ignacio; Hong, David S

AXL Inhibitors in Oncology Clinical Trials: A Review

AXL抑制剂在肿瘤临床试验中的应用:综述

Quach, Ethan; Sanginova, Farahnoz; Cheruku, Anish; Stack, Sophia; Falchook, Gerald S

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation

Zelenecide Pevedotin治疗晚期实体瘤患者的首次人体I/II期剂量递增和扩展研究:单药治疗剂量递增的结果

Baldini, Capucine; Verlingue, Loic; Goldschmidt, Vincent; Doger de Spéville, Bernard; Lostes, Julia; Italiano, Antoine; Cousin, Sophie; Falchook, Gerald S; Necchi, Andrea; Reig Torras, Oscar; Fontana, Elisa; Carter, Louise; Rodon Ahnert, Jordi; Brown, Jason R; DeMars, Leslie R; Josephs, Kate; Dickson, Amy; Xu, Cong; Bader, Justin; Campbell, Carly; Sharma, Rajiv; McKean, Meredith

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

TNG260 是一种小分子 CoREST 抑制剂,可使 STK11 突变肿瘤对 PD-1 抗肿瘤免疫疗法敏感。

Ahronian Leanne G, Sahu Soumyadip, Zhang Minjie, Patel Ayushi S, Geng Ke, Bhattacharya Reshmee, Falchook Gerald S, Goldman Jonathan W, Spira Alexander I, Punekar Salman R, Spigel David R, Wang Judy S, Skoulidis Ferdinandos, Stephens Janaye, Meynardie Mary, Powell Jaylen M, Lopez Alfonso, Ranieri Michela, Ploszaj Magdalena A, Tan Yi Jer, Lee Yeuan Ting, Yu Yi, Deng Jiehui, Chen Ting, McCarren Patrick, Tsai Alice, Hussain Suleman S, Doyon Brian, Amemiya Kenjie, Ermolieff Jacques, Shahagadkar Preksha, Das Nikitha M, Flynn Lauren R, Shields Julie A, Danielczyk Laney, McMillan Brian J, Mignault Andre, Meier Samuel R, Wu Hsin-Jung, Guerin David J, Whittington Douglas A, Min Chengyin, Sienczylo Iga, Maxwell John P, DiBenedetto Heather J, Watanabe Hideo, Haines Brian B, Huang Alan, Crystal Adam, Andersen Jannik N, Wu Xinyuan, Wong Kwok-Kin

A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects.

vocimagene amiretrorepvec 在晚期实体瘤患者中的 1B 期试验:安全性、肿瘤归巢和免疫调节作用。

Merchan Jaime R, Rodon Jordi, Venkat Shree, Donahue Arthur, Thomassen Amber, Accomando William P, Rodriguez-Aguirre Maria, Kwon Deukwoo, Bentley Cornelia, Hogan Daniel J, Rodrigues Olivia Roos, Yavrom Sharon, Ostertag Derek, Shorr Jolene, Falchook Gerald S

A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma

一项 Ib 期研究评估 c-MET 抑制剂 INC280(卡马替尼)联合贝伐单抗治疗高级别胶质瘤患者的疗效

Falchook, Gerald S; Battiste, James D; Kalra, Amandeep; Shastry, Mythili; Finney, Lindsey; Hoekstra, Susan J; Shih, Meredith G; Shih, Kent C

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

一项开放标签、多中心、I期研究,旨在评估Adavosertib联合Durvalumab治疗晚期实体瘤患者的安全性和耐受性

Patel, Manish R; Falchook, Gerald S; Wang, Judy S; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Miah, Kowser; Mugundu, Ganesh M; Jones, Suzanne F; Spigel, David R; Hamilton, Erika P

Oncology Clinical Trials Targeting Members of the Cadherin Superfamily: A Review

针对钙黏蛋白超家族成员的肿瘤临床试验:综述

Keeling, Jacob; Falchook, Gerald

4-1BB Antibodies in Oncology Clinical Trials: A Review

4-1BB抗体在肿瘤临床试验中的应用:综述

Schwartz, Robin; Vajrala, Keerti; Falchook, Gerald S

Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A Review

肿瘤临床试验中细胞周期蛋白依赖性激酶2 (CDK2) 抑制剂的应用:综述

House, Isabelle; Valore-Caplan, Mari; Maris, Elijah; Falchook, Gerald S